560 lines
No EOL
151 KiB
HTML
560 lines
No EOL
151 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK65935" /><meta name="ncbi_domain" content="pdqcis" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK65935.1/" /><meta name="ncbi_pagename" content="Childhood Ependymoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Childhood Ependymoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="author" content="PDQ Pediatric Treatment Editorial Board" /><meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]" /><meta name="citation_title" content="Childhood Ependymoma Treatment (PDQ®)" /><meta name="citation_publisher" content="National Cancer Institute (US)" /><meta name="citation_date" content="2015/08/14" /><meta name="citation_author" content="PDQ Pediatric Treatment Editorial Board" /><meta name="citation_pmid" content="26389373" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK65935/" /><meta name="citation_keywords" content="childhood ependymoma" /><meta name="citation_keywords" content="childhood brain tumor" /><meta name="citation_keywords" content="childhood ependymoma" /><meta name="citation_keywords" content="childhood brain tumor" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Childhood Ependymoma Treatment (PDQ®)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Cancer Institute (US)" /><meta name="DC.Contributor" content="PDQ Pediatric Treatment Editorial Board" /><meta name="DC.Date" content="2015/08/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK65935/" /><meta name="DC.Language" content="en" /><meta name="description" content="Expert-reviewed information summary about the treatment of childhood ependymoma." /><meta name="og:title" content="Childhood Ependymoma Treatment (PDQ®)" /><meta name="og:type" content="book" /><meta name="og:description" content="Expert-reviewed information summary about the treatment of childhood ependymoma." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK65935/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000062843/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK65935/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C16FC7C9A15810000000000060004.m_14" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
<div id="universal_header">
|
|
<section class="usa-banner">
|
|
<div class="usa-accordion">
|
|
<header class="usa-banner-header">
|
|
<div class="usa-grid usa-banner-inner">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
|
<p>An official website of the United States government</p>
|
|
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
|
<span class="usa-banner-button-text">Here's how you know</span>
|
|
</button>
|
|
</div>
|
|
</header>
|
|
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
|
<div class="usa-banner-guidance-gov usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The .gov means it's official.</strong>
|
|
<br />
|
|
Federal government websites often end in .gov or .mil. Before
|
|
sharing sensitive information, make sure you're on a federal
|
|
government site.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The site is secure.</strong>
|
|
<br />
|
|
The <strong>https://</strong> ensures that you are connecting to the
|
|
official website and that any information you provide is encrypted
|
|
and transmitted securely.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<div class="usa-overlay"></div>
|
|
<header class="ncbi-header" role="banner" data-section="Header">
|
|
|
|
<div class="usa-grid">
|
|
<div class="usa-width-one-whole">
|
|
|
|
<div class="ncbi-header__logo">
|
|
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
|
</a>
|
|
</div>
|
|
|
|
<div class="ncbi-header__account">
|
|
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
|
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
|
<span class="fa fa-user" aria-hidden="true">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
|
<g style="fill: #fff">
|
|
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
|
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
|
</g>
|
|
</svg>
|
|
</span>
|
|
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
|
<span class="sr-only">Show account info</span>
|
|
</button>
|
|
</div>
|
|
|
|
<div class="ncbi-popup-anchor">
|
|
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
|
<div class="ncbi-popup-head">
|
|
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
|
<span class="fa fa-times">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
|
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
|
</svg>
|
|
</span>
|
|
<span class="usa-sr-only">Close</span></button>
|
|
<h4>Account</h4>
|
|
</div>
|
|
<div class="account-user-info">
|
|
Logged in as:<br />
|
|
<b><span class="username" id="uname_long">username</span></b>
|
|
</div>
|
|
<div class="account-links">
|
|
<ul class="usa-unstyled-list">
|
|
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
|
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
|
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
|
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
|
</ul>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
</div>
|
|
</header>
|
|
<div role="navigation" aria-label="access keys">
|
|
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
|
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
|
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
|
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
|
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
|
</div>
|
|
<section data-section="Alerts">
|
|
<div class="ncbi-alerts-placeholder"></div>
|
|
</section>
|
|
</div>
|
|
<div class="header">
|
|
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
|
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="snp">SNP</option><option value="nlmcatalog">NLM Catalog</option><option value="pcsubstance" class="last">PubChem Substance</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
|
<a href="/books/browse/">Browse Titles</a>
|
|
</li><li>
|
|
<a href="/books/advanced/">Advanced</a>
|
|
</li><li class="help">
|
|
<a href="/books/NBK3833/">Help</a>
|
|
</li><li class="disclaimer">
|
|
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
|
</li></ul></div>
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<!-- Custom content 1 -->
|
|
<div class="col1">
|
|
|
|
</div>
|
|
|
|
<div class="container">
|
|
<div id="maincontent" class="content eight_col col">
|
|
<!-- Custom content in the left column above book nav -->
|
|
<div class="col2">
|
|
|
|
</div>
|
|
|
|
<!-- Book content -->
|
|
|
|
|
|
<!-- Custom content between navigation and content -->
|
|
<div class="col3">
|
|
|
|
</div>
|
|
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/pdqcis/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" alt="Cover of PDQ Cancer Information Summaries" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>PDQ Cancer Information Summaries [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK65935_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK65935_dtls__"><div>Bethesda (MD): <a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>; 2002-.</div></div><div class="half_rhythm"></div><div class="bk_noprnt"><form method="get" action="/books/n/pdqcis/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK65935_"><span class="title" itemprop="name">Childhood Ependymoma Treatment (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contrib-group"><span itemprop="author">PDQ Pediatric Treatment Editorial Board</span>.</p><p class="small">Published online: August 14, 2015.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000062843__420">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood ependymoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000062843__421">This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000062843__1"><h2 id="_CDR0000062843__1_">General Information About Childhood Ependymoma</h2><p id="CDR0000062843__267">The PDQ childhood brain tumor treatment summaries are organized primarily according to the World Health Organization (WHO) classification of nervous system tumors.[<a class="bk_pop" href="#CDR0000062843_rl_1_1">1</a>,<a class="bk_pop" href="#CDR0000062843_rl_1_2">2</a>] For a full description of the classification of nervous system tumors and a link to the corresponding treatment summary for each type of brain tumor, refer to the PDQ summary on <a href="/books/n/pdqcis/CDR0000062680/">Childhood Brain and Spinal Cord Tumors Treatment Overview</a>.</p><p id="CDR0000062843__87">Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[<a class="bk_pop" href="#CDR0000062843_rl_1_3">3</a>] Childhood and adolescent cancer survivors require close follow-up because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary <a href="/books/n/pdqcis/CDR0000343584/">Late Effects of Treatment for Childhood Cancer</a> for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.)</p><p id="CDR0000062843__3">Primary brain tumors are a diverse group of diseases that together constitute the most common solid tumor of childhood. Immunohistochemical analysis, cytogenetic and molecular genetic findings, and measures of mitotic activity are increasingly used in tumor diagnosis and classification. Brain tumors are classified according to histology, but tumor location and extent of spread are important factors that affect treatment and prognosis.</p><p id="CDR0000062843__381">Ependymomas arise from ependymal cells that line the ventricles and passageways in the brain and the center of the spinal cord. Ependymal cells produce cerebrospinal fluid (CSF). These tumors are classified as supratentorial or infratentorial. In children, most ependymomas are infratentorial tumors that arise in or around the fourth ventricle. According to the WHO classification of brain tumors, ependymal tumors are classified into the following four main subtypes:</p><ul id="CDR0000062843__382"><li class="half_rhythm"><div>Subependymoma (WHO Grade I).</div></li><li class="half_rhythm"><div>Myxopapillary ependymoma (WHO Grade I).</div></li><li class="half_rhythm"><div>Ependymoma (WHO Grade II).</div></li><li class="half_rhythm"><div>Anaplastic ependymoma (WHO Grade III).</div></li></ul><p id="CDR0000062843__383">The location of the tumor determines the clinical presentation. Treatment begins with surgery. The type of adjuvant therapy given, such as a second surgery, chemotherapy, or radiation therapy, depends on the following: </p><ul id="CDR0000062843__398"><li class="half_rhythm"><div>Subtype of ependymoma.</div></li><li class="half_rhythm"><div>Whether the tumor was completely removed during the initial surgery.</div></li><li class="half_rhythm"><div>Whether the tumor has disseminated throughout the central nervous system.</div></li><li class="half_rhythm"><div>Child's age.</div></li></ul><div id="CDR0000062843__180"><h3>Incidence</h3><p id="CDR0000062843__167">Childhood ependymoma comprises approximately 9% of all childhood brain tumors, representing about 200 cases per year in the United States.[<a class="bk_pop" href="#CDR0000062843_rl_1_4">4</a>,<a class="bk_pop" href="#CDR0000062843_rl_1_5">5</a>]</p></div><div id="CDR0000062843__353"><h3>Anatomy</h3><a id="CDR0000062843__354"></a><div class="iconblock whole_rhythm clearfix ten_col fig" id="figCDR0000062843355" co-legend-rid="figlgndCDR0000062843355"><a href="/books/NBK65935.1/figure/CDR0000062843__355/?report=objectonly" target="object" title="Figure" class="img_link icnblk_img figpopup" rid-figpopup="figCDR0000062843355" rid-ob="figobCDR0000062843355"><img class="small-thumb" src="/books/NBK65935.1/bin/CDR0000748659.gif" src-large="/books/NBK65935.1/bin/CDR0000748659.jpg" alt="Anatomy of the inside of the brain, showing the pineal and pituitary glands, optic nerve, ventricles (with cerebrospinal fluid shown in blue), and other parts of the brain" /></a><div class="icnblk_cntnt" id="figlgndCDR0000062843355"><h4 id="CDR0000062843__355"><a href="/books/NBK65935.1/figure/CDR0000062843__355/?report=objectonly" target="object" rid-ob="figobCDR0000062843355">Figure</a></h4><p class="float-caption no_bottom_margin">Anatomy of the inside of the brain, showing the pineal and pituitary glands, optic nerve, ventricles (with cerebrospinal fluid shown in blue), and other parts of the brain. The tentorium separates the cerebrum from the cerebellum. The infratentorium (posterior <a href="/books/NBK65935.1/figure/CDR0000062843__355/?report=objectonly" target="object" rid-ob="figobCDR0000062843355">(more...)</a></p></div></div></div><div id="CDR0000062843__342"><h3>Clinical Features</h3><p id="CDR0000062843__343">The clinical presentation of ependymoma is dependent on tumor location. </p><ul id="CDR0000062843__384"><li class="half_rhythm"><div><b>Infratentorial (posterior fossa) ependymoma:</b> In children, approximately 65% to 75% of ependymomas arise in the posterior fossa.[<a class="bk_pop" href="#CDR0000062843_rl_1_6">6</a>] Children with posterior fossa ependymoma may present with signs and symptoms of obstructive hydrocephalus due to obstruction at the level of the fourth ventricle. They may also present with ataxia, neck pain, or cranial nerve palsies.</div></li><li class="half_rhythm"><div><b>Supratentorial ependymoma:</b> Supratentorial ependymoma may result in headache, seizures, or location-dependent focal neurologic deficits.</div></li><li class="half_rhythm"><div><b>Spinal cord ependymoma:</b> Spinal cord ependymomas, which are often the myxopapillary variant, tend to cause back pain, lower extremity weakness, and/or bowel and bladder dysfunction.</div></li></ul></div><div id="CDR0000062843__291"><h3>Diagnostic Evaluation</h3><p id="CDR0000062843__292">Every patient suspected of having ependymoma should be
|
|
evaluated with diagnostic imaging of the whole brain and spinal cord. The most
|
|
sensitive method available for evaluating spinal cord subarachnoid metastasis
|
|
is spinal magnetic resonance imaging (MRI) performed with gadolinium. This is ideally done before surgery to avoid confusion with postoperative blood. If MRI
|
|
is used, the entire spine is generally imaged in at least two planes with contiguous
|
|
MRI slices performed after gadolinium enhancement. If feasible, CSF cytological evaluation should be conducted.[<a class="bk_pop" href="#CDR0000062843_rl_1_7">7</a>] </p></div><div id="CDR0000062843__287"><h3>Prognostic Factors</h3><p id="CDR0000062843__288">Unfavorable factors affecting outcome (except as noted) include the following:</p><ul id="CDR0000062843__289"><li class="half_rhythm"><div class="half_rhythm">Gain of chromosome 1q25. Gain of chromosome 1q25 is present in approximately 20% of pediatric intracranial ependymoma cases and has been reported as a negative prognostic factor by multiple research groups.[<a class="bk_pop" href="#CDR0000062843_rl_1_8">8</a>-<a class="bk_pop" href="#CDR0000062843_rl_1_11">11</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Gene expression profile. </div><div class="half_rhythm">Posterior fossa ependymoma can be divided into the following two groups based on distinctive patterns of gene expression.[<a class="bk_pop" href="#CDR0000062843_rl_1_12">12</a>,<a class="bk_pop" href="#CDR0000062843_rl_1_13">13</a>]<dl id="CDR0000062843__290" class="temp-labeled-list"><dt>-</dt><dd><p class="no_top_margin">One expression-defined group occurs primarily in young children and is characterized by a largely balanced genomic profile with an increased occurrence of chromosome 1q gain and expression of genes and proteins previously shown to be associated with poor prognosis, such as tenascin C and epidermal growth factor receptor.[<a class="bk_pop" href="#CDR0000062843_rl_1_8">8</a>,<a class="bk_pop" href="#CDR0000062843_rl_1_14">14</a>]</p></dd><dt>-</dt><dd><p class="no_top_margin">The second expression-defined group occurs primarily in older children and adults and is characterized by a more favorable prognosis and by numerous cytogenetic abnormalities involving whole chromosomes or chromosomal arms.[<a class="bk_pop" href="#CDR0000062843_rl_1_12">12</a>]</p></dd></dl></div><div class="half_rhythm">Other factors that have been reported to be associated with poor prognosis for pediatric ependymoma include expression of the enzymatic subunit of telomerase (hTERT) [<a class="bk_pop" href="#CDR0000062843_rl_1_15">15</a>-<a class="bk_pop" href="#CDR0000062843_rl_1_17">17</a>] and expression of the neural stem cell marker Nestin.[<a class="bk_pop" href="#CDR0000062843_rl_1_18">18</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335150/" class="def">Level of evidence: 3iiiA</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Tumor location. Cranial variants of ependymoma have a less favorable outcome than primary spinal cord ependymomas.[<a class="bk_pop" href="#CDR0000062843_rl_1_19">19</a>,<a class="bk_pop" href="#CDR0000062843_rl_1_20">20</a>] Location within the spinal cord may also affect outcome, with tumors in the lower portion of the spinal cord having a worse prognosis.[<a class="bk_pop" href="#CDR0000062843_rl_1_21">21</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335150/" class="def">Level of evidence: 3iiiA</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Younger age at diagnosis.[<a class="bk_pop" href="#CDR0000062843_rl_1_22">22</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335155/" class="def">Level of evidence: 3iiiDii</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Anaplastic histology.[<a class="bk_pop" href="#CDR0000062843_rl_1_22">22</a>-<a class="bk_pop" href="#CDR0000062843_rl_1_24">24</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_1_25">25</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335138/" class="def">Level of evidence: 3iA</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_1_26">26</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335153/" class="def">Level of evidence: 3iiiDi</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Subtotal resection.[<a class="bk_pop" href="#CDR0000062843_rl_1_22">22</a>] </div></li><li class="half_rhythm"><div class="half_rhythm">Lower doses of radiation.[<a class="bk_pop" href="#CDR0000062843_rl_1_27">27</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Higher proliferation marker.[<a class="bk_pop" href="#CDR0000062843_rl_1_28">28</a>,<a class="bk_pop" href="#CDR0000062843_rl_1_29">29</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">MIB-1 labeling index.[<a class="bk_pop" href="#CDR0000062843_rl_1_29">29</a>] </div></li></ul></div><div id="CDR0000062843__344"><h3>Follow-up After Treatment</h3><p id="CDR0000062843__345">Surveillance neuroimaging, coupled with clinical assessments, are generally recommended after treatment for ependymoma. The frequency and duration have been arbitrarily determined and the utility is uncertain.[<a class="bk_pop" href="#CDR0000062843_rl_1_30">30</a>] Most practitioners obtain MRI imaging of the brain and/or spinal cord every 3 months for the first 1 to 2 years after treatment. After 2 years, imaging every 6 months for the next 3 years is often undertaken.</p></div><div id="CDR0000062843_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062843_rl_1_1">Louis DN, Ohgaki H, Wiestler OD, et al., eds.: WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC Press, 2007. [<a href="/pmc/articles/PMC1929165/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1929165</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17618441" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17618441</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_2">Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 (2): 97-109, 2007. [<a href="/pmc/articles/PMC1929165/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1929165</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17618441" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17618441</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_3">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. [<a href="/pmc/articles/PMC4136455/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4136455</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24853691" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24853691</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_4">Gurney JG, Smith MA, Bunin GR: CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries LA, Smith MA, Gurney JG, et al., eds.: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649., Chapter 3, pp 51-63. <a href="http://seer.cancer.gov/archive/publications/childhood/childhood-monograph.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Also available online</a>. Last accessed August 14, 2015.</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_5">Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the
|
|
United States, 1997-2001. Hinsdale, Ill: Central Brain Tumor Registry of the United States, 2004. <a href="http://www.cbtrus.org/reports//2004-2005/2005report.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Also available online</a>. Last accessed August 14, 2015.</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_6">Andreiuolo F, Puget S, Peyre M, et al.: Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro Oncol 12 (11): 1126-34, 2010. [<a href="/pmc/articles/PMC3098029/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3098029</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20615923" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20615923</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_7">Moreno L, Pollack IF, Duffner PK, et al.: Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma. J Pediatr Hematol Oncol 32 (6): 515-8, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20463607" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20463607</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_8">Mendrzyk F, Korshunov A, Benner A, et al.: Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12 (7 Pt 1): 2070-9, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16609018" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16609018</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_9">Korshunov A, Witt H, Hielscher T, et al.: Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28 (19): 3182-90, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20516456" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20516456</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_10">Kilday JP, Mitra B, Domerg C, et al.: Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 18 (7): 2001-11, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22338015" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22338015</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_11">Godfraind C, Kaczmarska JM, Kocak M, et al.: Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol 124 (2): 247-57, 2012. [<a href="/pmc/articles/PMC3554251/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3554251</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22526017" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22526017</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_12">Wani K, Armstrong TS, Vera-Bolanos E, et al.: A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123 (5): 727-38, 2012. [<a href="/pmc/articles/PMC4013829/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4013829</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22322993" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22322993</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_13">Witt H, Mack SC, Ryzhova M, et al.: Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20 (2): 143-57, 2011. [<a href="/pmc/articles/PMC4154494/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4154494</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21840481" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21840481</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_14">Korshunov A, Golanov A, Timirgaz V: Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 177 (1): 72-82, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10967185" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10967185</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_15">Tabori U, Ma J, Carter M, et al.: Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 24 (10): 1522-8, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16575002" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16575002</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_16">Tabori U, Wong V, Ma J, et al.: Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer 99 (7): 1129-35, 2008. [<a href="/pmc/articles/PMC2567068/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2567068</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18797459" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18797459</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_17">Modena P, Buttarelli FR, Miceli R, et al.: Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro Oncol 14 (11): 1346-56, 2012. [<a href="/pmc/articles/PMC3480268/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3480268</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23076205" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23076205</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_18">Milde T, Hielscher T, Witt H, et al.: Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 22 (6): 848-60, 2012. [<a href="/pmc/articles/PMC8057643/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8057643</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22568867" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22568867</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_19">McGuire CS, Sainani KL, Fisher PG: Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 52 (1): 65-9, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19006249" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19006249</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_20">Benesch M, Frappaz D, Massimino M: Spinal cord ependymomas in children and adolescents. Childs Nerv Syst 28 (12): 2017-28, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22961356" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22961356</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_21">Oh MC, Sayegh ET, Safaee M, et al.: Prognosis by tumor location for pediatric spinal cord ependymomas. J Neurosurg Pediatr 11 (3): 282-8, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23259510" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23259510</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_22">Tamburrini G, D'Ercole M, Pettorini BL, et al.: Survival following treatment for intracranial ependymoma: a review. Childs Nerv Syst 25 (10): 1303-12, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19387655" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19387655</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_23">Merchant TE, Jenkins JJ, Burger PC, et al.: Influence of tumor grade on time to progression after irradiation for localized ependymoma in children. Int J Radiat Oncol Biol Phys 53 (1): 52-7, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12007941" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12007941</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_24">Korshunov A, Golanov A, Sycheva R, et al.: The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 100 (6): 1230-7, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15022291" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15022291</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_25">Amirian ES, Armstrong TS, Aldape KD, et al.: Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology 39 (2): 116-24, 2012. [<a href="/pmc/articles/PMC3470871/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3470871</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22846789" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22846789</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_26">Tihan T, Zhou T, Holmes E, et al.: The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 21 (2): 165-77, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18084249" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18084249</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_27">Vaidya K, Smee R, Williams JR: Prognostic factors and treatment options for paediatric ependymomas. J Clin Neurosci 19 (9): 1228-35, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22840355" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22840355</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_28">Wolfsberger S, Fischer I, Höftberger R, et al.: Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 28 (7): 914-20, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15223962" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15223962</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_29">Kurt E, Zheng PP, Hop WC, et al.: Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 106 (2): 388-95, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16342252" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16342252</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_1_30">Good CD, Wade AM, Hayward RD, et al.: Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long? J Neurosurg 94 (1): 27-32, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11147894" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11147894</span></a>]</div></li></ol></div></div><div id="CDR0000062843__35"><h2 id="_CDR0000062843__35_"> Histopathologic Classification of Childhood Ependymal Tumors</h2><p id="CDR0000062843__36">In the most recent World Health Organization (WHO) classification of brain tumors, ependymal tumors are classified into the following four main subtypes:[<a class="bk_pop" href="#CDR0000062843_rl_35_1">1</a>]
|
|
</p><ol id="CDR0000062843__387"><li class="half_rhythm"><div class="half_rhythm"><b>Subependymoma (WHO Grade I):</b> A subependymoma is a slow-growing neoplasm, typically attached to the ventricle wall and is composed of glial tumor cell clusters embedded in a fibrillary matrix. </div><div class="half_rhythm">The true incidence of subependymomas (WHO Grade I) is difficult to determine. These tumors are frequently asymptomatic and may be found incidentally at autopsy. Subependymomas probably comprise less than 5% of all ependymal tumors. </div></li><li class="half_rhythm"><div class="half_rhythm"><b>Myxopapillary ependymoma (WHO Grade I):</b> A myxopapillary ependymoma arises almost exclusively in the location of the conus medullaris, cauda equina, and filum terminale of the spinal cord and is characterized histologically by tumor cells arranged in a papillary manner around vascularized myxoid stromal cores.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Ependymoma (WHO Grade II): </b>The ependymoma, which is considered a Grade II neoplasm originating from the walls of the ventricles or from the spinal canal, is composed of neoplastic ependymal cells. Ependymomas are subdivided, based on histological findings, into the following four subtypes:<ul id="CDR0000062843__293"><li class="half_rhythm"><div>Cellular ependymoma—the most common subtype; usually demonstrates significant cellularity without an increase in mitotic activity.</div></li><li class="half_rhythm"><div>Papillary ependymoma—forms linear, epithelial-like surfaces along cerebrospinal fluid exposures.</div></li><li class="half_rhythm"><div>Clear cell ependymoma—displays an oligodendroglial-like appearance with perinuclear halos; this variant is preferentially located in the supratentorial compartment of the brain.</div></li><li class="half_rhythm"><div>Tanycytic ependymoma—the rarest form of Grade II ependymoma; most commonly found in the spinal cord; tumor cells are arranged in fascicles of variable width and cell density and are poorly intertwined.</div></li></ul></div></li><li class="half_rhythm"><div class="half_rhythm"><b>Anaplastic ependymoma (WHO Grade III):</b> Also known as malignant ependymoma. An anaplastic ependymoma is considered a malignant glioma of ependymal differentiation and, compared with the Grade II ependymomas, shows increased cellularity and increased mitotic activity, often associated with microvascular proliferation and necrosis.</div></li></ol><p id="CDR0000062843__255">In children, approximately 65% to 75% of ependymomas arise in the posterior fossa. Although supratentorial and infratentorial ependymomas are believed to arise from radial glia cells, they have different genomic, gene expression, and immunohistochemical signatures.[<a class="bk_pop" href="#CDR0000062843_rl_35_2">2</a>-<a class="bk_pop" href="#CDR0000062843_rl_35_4">4</a>] Supratentorial tumors are more often characterized by neuronal differentiation.[<a class="bk_pop" href="#CDR0000062843_rl_35_3">3</a>]</p><p id="CDR0000062843__244">Subependymomas and myxopapillary ependymomas are usually considered to be clinically and pathologically distinct from the Grade II and Grade III ependymomas. In Grade II and Grade III ependymomas, the relationship between histological features and survival has varied among studies, although most recent larger studies and meta-analyses have demonstrated that histological grade is an independent predictor of event-free survival.[<a class="bk_pop" href="#CDR0000062843_rl_35_5">5</a>-<a class="bk_pop" href="#CDR0000062843_rl_35_7">7</a>] A single-institution study suggests that patients with clear-cell ependymomas may have a higher risk of treatment failure than do patients with other forms of WHO Grade II ependymomas;[<a class="bk_pop" href="#CDR0000062843_rl_35_8">8</a>] however, confirmation is required in a larger group of unselected patients.</p><p id="CDR0000062843__236">Ependymoblastomas, which generally
|
|
behave more like medulloblastomas or cerebral neuroectodermal tumors, are
|
|
considered separate entities from ependymomas and are now classified with the embryonal tumors.[<a class="bk_pop" href="#CDR0000062843_rl_35_1">1</a>,<a class="bk_pop" href="#CDR0000062843_rl_35_5">5</a>] (Refer to the PDQ summary on <a href="/books/n/pdqcis/CDR0000548358/">Childhood Central Nervous System Embryonal Tumors Treatment</a> for more information.)</p><p id="CDR0000062843__39">The pathologic
|
|
classification of pediatric brain tumors is a specialized area that is
|
|
evolving; review of the diagnostic tissue by a neuropathologist who
|
|
has particular expertise in this area is strongly recommended.
|
|
</p><div id="CDR0000062843_rl_35"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062843_rl_35_1">Louis DN, Ohgaki H, Wiestler OD, et al., eds.: WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC Press, 2007. [<a href="/pmc/articles/PMC1929165/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1929165</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17618441" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17618441</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_35_2">Taylor MD, Poppleton H, Fuller C, et al.: Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8 (4): 323-35, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16226707" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16226707</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_35_3">Andreiuolo F, Puget S, Peyre M, et al.: Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro Oncol 12 (11): 1126-34, 2010. [<a href="/pmc/articles/PMC3098029/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3098029</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20615923" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20615923</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_35_4">Grill J, Bergthold G, Ferreira C: Pediatric ependymomas: will molecular biology change patient management? Curr Opin Oncol 23 (6): 638-42, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21892086" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21892086</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_35_5">Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 (2): 97-109, 2007. [<a href="/pmc/articles/PMC1929165/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1929165</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17618441" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17618441</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_35_6">Tihan T, Zhou T, Holmes E, et al.: The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 21 (2): 165-77, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18084249" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18084249</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_35_7">Shu HK, Sall WF, Maity A, et al.: Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer 110 (2): 432-41, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17559078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17559078</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_35_8">Fouladi M, Helton K, Dalton J, et al.: Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer 98 (10): 2232-44, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/14601094" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14601094</span></a>]</div></li></ol></div></div><div id="CDR0000062843__40"><h2 id="_CDR0000062843__40_">Stage Information for Childhood Ependymoma</h2><p id="CDR0000062843__41">Although there is no formal staging system, ependymomas can be divided into
|
|
supratentorial, infratentorial, and spinal tumors. Approximately 30% of childhood ependymomas arise in supratentorial regions of the brain and 70% arise in the posterior fossa.[<a class="bk_pop" href="#CDR0000062843_rl_40_1">1</a>] They usually originate in the
|
|
ependymal linings of ventricles or central canal or ventriculus terminalis of the spinal cord and have access to the cerebrospinal fluid. Therefore, these tumors may
|
|
spread throughout the neuraxis, although dissemination is noted in less than 10% of patients with Grade II and Grade III ependymomas. Myxopapillary ependymomas are more likely to disseminate to the nervous system early in the course of illness. </p><div id="CDR0000062843_rl_40"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062843_rl_40_1">Villano JL, Parker CK, Dolecek TA: Descriptive epidemiology of ependymal tumours in the United States. Br J Cancer 108 (11): 2367-71, 2013. [<a href="/pmc/articles/PMC3681017/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3681017</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23660944" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23660944</span></a>]</div></li></ol></div></div><div id="CDR0000062843__42"><h2 id="_CDR0000062843__42_">Treatment Option Overview for Childhood Ependymoma</h2><p id="CDR0000062843__43">Many of the improvements in survival in childhood cancer have been made as a
|
|
result of clinical trials that have attempted to improve on the best available,
|
|
accepted therapy. Clinical trials in pediatrics are designed to compare new
|
|
therapy with therapy that is currently accepted as standard. This comparison
|
|
may be done in a randomized study of two treatment arms or by evaluating a single
|
|
new treatment and comparing the results with those previously obtained with
|
|
existing therapy.
|
|
</p><p id="CDR0000062843__44">Because of the relative rarity of cancer in children, all patients with aggressive brain
|
|
tumors should be considered for entry into a clinical trial. To determine and
|
|
implement optimum treatment, treatment planning by a multidisciplinary team of
|
|
cancer specialists who have experience treating childhood brain tumors is
|
|
required. Radiation therapy of pediatric brain tumors is technically demanding and should be performed in centers that have experience in that
|
|
area to ensure optimal results.
|
|
</p><div id="CDR0000062843__346" class="table"><h3><span class="title">Table 1. Standard Treatment Options for Childhood Ependymoma</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK65935.1/table/CDR0000062843__346/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062843__346_lrgtbl__"><table class="no_top_margin"><thead><tr><th colspan="2" rowspan="1" style="vertical-align:top;">Stage and/or Histopathologic Classification</th><th colspan="1" rowspan="1" style="vertical-align:top;">Standard Treatment Options</th></tr></thead><tbody><tr><td colspan="2" rowspan="2" style="vertical-align:top;">Newly diagnosed childhood subependymoma</td><td colspan="1" rowspan="1" style="vertical-align:top;"><a href="#CDR0000062843__299">Surgery</a></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"><a href="#CDR0000062843__299">Observation (in rare cases)</a></td></tr><tr><td colspan="2" rowspan="1" style="vertical-align:top;">Newly diagnosed childhood myxopapillary ependymoma</td><td colspan="1" rowspan="1" style="vertical-align:top;"><a href="#CDR0000062843__303">Surgery with or without radiation therapy</a></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top;">Newly diagnosed childhood ependymoma (WHO Grade II) or anaplastic ependymoma (WHO Grade III):</td><td colspan="1" rowspan="1" style="vertical-align:top;"><a href="#CDR0000062843__309">Surgery</a></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"><a href="#CDR0000062843__117">Adjuvant therapy</a>:</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"></td><td colspan="1" rowspan="1" style="vertical-align:top;">No residual disease, no disseminated disease</td><td colspan="1" rowspan="1" style="vertical-align:top;">—<a href="#CDR0000062843__359">Radiation therapy</a></td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;"></td><td colspan="1" rowspan="3" style="vertical-align:top;">Residual disease, no disseminated disease</td><td colspan="1" rowspan="1" style="vertical-align:top;">—<a href="#CDR0000062843__361">Second-look surgery</a></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">—<a href="#CDR0000062843__362">Radiation therapy</a></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">—<a href="#CDR0000062843__364">Preirradiation chemotherapy</a></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"></td><td colspan="1" rowspan="1" style="vertical-align:top;">Central nervous system disseminated disease</td><td colspan="1" rowspan="1" style="vertical-align:top;">—<a href="#CDR0000062843__367">Radiation therapy</a></td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;"></td><td colspan="1" rowspan="2" style="vertical-align:top;">Children younger than 3 years</td><td colspan="1" rowspan="1" style="vertical-align:top;">—<a href="#CDR0000062843__370">Chemotherapy</a></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">—<a href="#CDR0000062843__373">Radiation therapy</a></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top;">Recurrent childhood ependymoma</td><td colspan="1" rowspan="1" style="vertical-align:top;"><a href="#CDR0000062843__375">Surgery</a></td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"><a href="#CDR0000062843__377">Radiation therapy and/or chemotherapy</a>
|
|
</td></tr></tbody></table></div></div></div><div id="CDR0000062843__298"><h2 id="_CDR0000062843__298_">Treatment of Newly Diagnosed Childhood Subependymoma</h2><p id="CDR0000062843__299">The standard treatment options for newly diagnosed subependymoma (WHO Grade I) include the following:</p><ol id="CDR0000062843__347"><li class="half_rhythm"><div>Surgery.</div></li><li class="half_rhythm"><div>Observation (in rare cases).</div></li></ol><p id="CDR0000062843__388">In cases requiring therapy, complete surgical removal is often curative. Some subependymomas are considered incidental findings and observed without intervention. </p><p id="CDR0000062843__331">Occasionally, subependymomas cause ventricular obstruction and, in these cases, ventriculoperitoneal shunt placement is indicated. Spontaneous intratumoral hemorrhage has also been observed.[<a class="bk_pop" href="#CDR0000062843_rl_298_1">1</a>] </p><div id="CDR0000062843_rl_298"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062843_rl_298_1">Waldron JS, Tihan T: Epidemiology and pathology of intraventricular tumors. Neurosurg Clin N Am 14 (4): 469-82, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/15024796" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15024796</span></a>]</div></li></ol></div></div><div id="CDR0000062843__302"><h2 id="_CDR0000062843__302_">Treatment of Newly Diagnosed Childhood Myxopapillary Ependymoma</h2><p id="CDR0000062843__389">Myxopapillary ependymomas, considered to be a histologic subtype of ependymoma, have a relatively high incidence of central nervous system tumor dissemination at diagnosis and at follow-up. Imaging of the complete craniospinal axis at the time of diagnosis and during follow-up is indicated.[<a class="bk_pop" href="#CDR0000062843_rl_302_1">1</a>,<a class="bk_pop" href="#CDR0000062843_rl_302_2">2</a>]</p><p id="CDR0000062843__303">Standard treatment options for newly diagnosed myxopapillary ependymoma (WHO Grade I) include the following:</p><ol id="CDR0000062843__348"><li class="half_rhythm"><div>Surgery with or without adjuvant radiation therapy.</div></li></ol><p id="CDR0000062843__305">Historically, the management of myxopapillary ependymoma (WHO Grade I) consisted of an attempt at en bloc resection of the tumor with no further treatment in the case of a gross-total resection.[<a class="bk_pop" href="#CDR0000062843_rl_302_3">3</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_302_4">4</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335153/" class="def">Level of evidence: 3iiiDi</a>] However, based on the finding that dissemination of these tumors to other parts of the neuraxis can occur, particularly when complete resection is not obtained, and evidence that focal radiation therapy may improve progression-free survival, many practitioners now favor the use of radiation therapy after surgical resection of the primary mass.[<a class="bk_pop" href="#CDR0000062843_rl_302_1">1</a>,<a class="bk_pop" href="#CDR0000062843_rl_302_3">3</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_302_5">5</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335153/" class="def">Level of evidence: 3iiiDi</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_302_6">6</a>,<a class="bk_pop" href="#CDR0000062843_rl_302_7">7</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335158/" class="def">Level of evidence: 3iiiDiii</a>]</p><div id="CDR0000062843_rl_302"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062843_rl_302_1">Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg 102 (1 Suppl): 59-64, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16206735" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16206735</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_302_2">Bagley CA, Kothbauer KF, Wilson S, et al.: Resection of myxopapillary ependymomas in children. J Neurosurg 106 (4 Suppl): 261-7, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17465358" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17465358</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_302_3">Akyurek S, Chang EL, Yu TK, et al.: Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center. J Neurooncol 80 (2): 177-83, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16648988" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16648988</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_302_4">Bagley CA, Wilson S, Kothbauer KF, et al.: Long term outcomes following surgical resection of myxopapillary ependymomas. Neurosurg Rev 32 (3): 321-34; discussion 334, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19221818" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19221818</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_302_5">Pica A, Miller R, Villà S, et al.: The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys 74 (4): 1114-20, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19250760" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19250760</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_302_6">Agbahiwe HC, Wharam M, Batra S, et al.: Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys 85 (2): 421-7, 2013. [<a href="/pmc/articles/PMC4613753/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4613753</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22713833" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22713833</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_302_7">Jeibmann A, Egensperger R, Kuchelmeister K, et al.: Extent of surgical resection but not myxopapillary versus classical histopathological subtype affects prognosis in lumbo-sacral ependymomas. Histopathology 54 (2): 260-2, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19207953" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19207953</span></a>]</div></li></ol></div></div><div id="CDR0000062843__48"><h2 id="_CDR0000062843__48_"> Treatment of Newly Diagnosed Childhood Ependymoma or Anaplastic Ependymoma</h2><p id="CDR0000062843__307">Standard treatment options for newly diagnosed ependymoma (WHO Grade II) or anaplastic ependymoma (WHO Grade III) include the following:</p><ol id="CDR0000062843__349"><li class="half_rhythm"><div><a href="#CDR0000062843__309">Surgery</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062843__117">Adjuvant therapy</a>.<ul id="CDR0000062843__399"><li class="half_rhythm"><div><a href="#CDR0000062843__118">Treatment options for no residual disease, no disseminated disease</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062843__319">Treatment options for residual disease, no disseminated disease</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062843__324">Treatment options for central nervous system (CNS) disseminated disease</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062843__328">Treatment options for children younger than 3 years</a>.</div></li></ul></div></li></ol><p id="CDR0000062843__356">Typically, all patients undergo surgery to remove the tumor. Whether additional treatment is given depends on the extent of tumor resection and whether there is disseminated disease.</p><div id="CDR0000062843__309"><h3>Surgery</h3><p id="CDR0000062843__310">Surgery should be
|
|
performed in an attempt at maximal tumor reduction. Evidence suggests that more extensive surgical resection is related to an improved rate of survival.[<a class="bk_pop" href="#CDR0000062843_rl_48_1">1</a>-<a class="bk_pop" href="#CDR0000062843_rl_48_5">5</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_48_6">6</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335142/" class="def">Level of evidence: 3iDii</a>] Magnetic resonance imaging (MRI) should be performed postoperatively to confirm the extent of resection. If not performed preoperatively, MRI of the entire neuraxis to evaluate disease dissemination and cerebrospinal fluid cytopathology should be performed. </p><p id="CDR0000062843__311">Patients with residual tumor or disseminated
|
|
disease should be considered at high risk for relapse and should be treated on
|
|
protocols specifically designed for them. Those with no evidence of residual
|
|
tumor still have an approximate 20% to 40% relapse risk in spite of
|
|
postoperative radiation therapy.
|
|
</p><p id="CDR0000062843__400">Anecdotal experience suggests that surgery alone for completely resected supratentorial nonanaplastic tumors and intradural spinal cord ependymomas may, in select cases, be an appropriate approach to treatment.[<a class="bk_pop" href="#CDR0000062843_rl_48_7">7</a>,<a class="bk_pop" href="#CDR0000062843_rl_48_8">8</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335153/" class="def">Level of evidence: 3iiiDi</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_48_9">9</a>,<a class="bk_pop" href="#CDR0000062843_rl_48_10">10</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335158/" class="def">Level of evidence: 3iiiDiii</a>] </p></div><div id="CDR0000062843__117"><h3>Adjuvant Therapy </h3><div id="CDR0000062843__118"><h4>Treatment options for no residual disease, no disseminated disease</h4><div id="CDR0000062843__359"><h5>Radiation therapy</h5><p id="CDR0000062843__312">The traditional postsurgical treatment for these patients has been radiation
|
|
therapy consisting of 54 Gy to 55.8 Gy to the tumor bed for children aged 3 years and older.[<a class="bk_pop" href="#CDR0000062843_rl_48_11">11</a>] It is not necessary
|
|
to treat the entire CNS (whole brain and spine) because these tumors usually
|
|
recur initially at the local site.[<a class="bk_pop" href="#CDR0000062843_rl_48_12">12</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_48_13">13</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335150/" class="def">Level of evidence: 3iiiA</a>] When possible, patients should be treated in a
|
|
center experienced with the delivery of highly <a href="/books/n/pdqcis/glossary/def-item/glossary_CDR0000270731/" class="def">conformal radiation therapy</a> (including <a href="/books/n/pdqcis/glossary/def-item/glossary_CDR0000335073/" class="def">intensity-modulated radiation therapy</a> or <a href="/books/n/pdqcis/glossary/def-item/glossary_CDR0000534234/" class="def">charged-particle radiation therapy</a>) to pediatric patients with brain tumors. </p><p id="CDR0000062843__315">Evidence (radiation therapy):</p><ol id="CDR0000062843__316"><li class="half_rhythm"><div>In one study, 74 patients aged 1 to 21 years were treated with radiation therapy after surgery.[<a class="bk_pop" href="#CDR0000062843_rl_48_14">14</a>] <ul id="CDR0000062843__317"><li class="half_rhythm"><div>The 3-year progression-free survival (PFS) rate was 77.6% ± 5.8%.</div></li></ul></div></li><li class="half_rhythm"><div>In a second series, 107 of 153 patients received conformal radiation therapy immediately after up-front resection.[<a class="bk_pop" href="#CDR0000062843_rl_48_5">5</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335138/" class="def">Level of evidence: 3iA</a>]<ul id="CDR0000062843__318"><li class="half_rhythm"><div>The 7-year event-free survival was 76.9% ± 13.5%.</div></li></ul>
|
|
</div></li></ol><p id="CDR0000062843__401">Focal radiation therapy has been used in certain cases.[<a class="bk_pop" href="#CDR0000062843_rl_48_15">15</a>] In a small series of children with localized ependymoma, surgery alone was compared with adjuvant radiation therapy. Adjuvant radiation therapy appeared to improve PFS, even after adjusting for the extent of resection. In fact, a PFS benefit was observed for patients who received adjuvant radiation therapy after gross-total resection, compared with those who did not receive radiation therapy.[<a class="bk_pop" href="#CDR0000062843_rl_48_16">16</a>] Additional research will be necessary to confirm these findings.</p><p id="CDR0000062843__416">Proton-beam radiation therapy (a type of <a href="/books/n/pdqcis/glossary/def-item/glossary_CDR0000534234/" class="def">charged-particle radiation therapy</a>) provides a possible advantage for targeting the tumor while avoiding critical normal brain and neuroendocrine tissues, whether the tumor is supratentorial or infratentorial. Seventy children treated with involved-field, proton-beam radiation at Massachusetts General Hospital between 2000 and 2011 (median age, 33 months; range, 3 months–20 years) had 3-year local control of 83%, PFS of 76%, and overall survival (OS) of 95%, with confirmation that subtotal resection was associated with an inferior outcome. Data demonstrating an advantage in terms of intelligence, adaptive skills, neuroendocrine deficiencies, and other morbidities do not yet show an advantage over other forms of conformal radiation therapy.[<a class="bk_pop" href="#CDR0000062843_rl_48_17">17</a>]</p></div><div id="CDR0000062843__360"><h5>Chemotherapy</h5><p id="CDR0000062843__313">There is no evidence to date that adjuvant
|
|
chemotherapy, including the use of myeloablative chemotherapy,[<a class="bk_pop" href="#CDR0000062843_rl_48_18">18</a>] improves the outcome for patients with totally resected, nondisseminated ependymoma. For this reason, current treatment approaches do not include chemotherapy as a standard component of primary therapy for children with newly diagnosed ependymomas that are completely resected.</p><p id="CDR0000062843__379">A randomized trial evaluating the efficacy of postradiation chemotherapy in children who have had a gross-total resection is underway.</p></div></div><div id="CDR0000062843__319"><h4>Treatment options for residual disease, no disseminated disease</h4><div id="CDR0000062843__361"><h5>Second-look surgery</h5><p id="CDR0000062843__320">Second-look surgery should be considered because patients who have complete
|
|
resections have better disease control.[<a class="bk_pop" href="#CDR0000062843_rl_48_19">19</a>] In some cases, further surgery can be undertaken after the initial attempted resection if the pediatric neurosurgeon believes that a gross-total resection could be obtained by an alternate surgical approach to the tumor. In other cases, further up-front surgery is not anticipated to result in a gross-total resection, therefore, adjuvant therapy is initiated with future consideration of second-look surgery.</p></div><div id="CDR0000062843__362"><h5>Radiation therapy</h5><p id="CDR0000062843__363">The rationale for radiation therapy as described in the <a href="#CDR0000062843__359">Treatment options for no residual disease, no disseminated disease</a> subsection above also pertains to the treatment of children with residual, nondisseminated ependymoma. In patients with a subtotal resection, treatment with radiation therapy results in 3-year to 5-year PFS in 30% to 50% of patients,[<a class="bk_pop" href="#CDR0000062843_rl_48_14">14</a>] although the outcome for patients with residual tumor within the spinal canal may be better.[<a class="bk_pop" href="#CDR0000062843_rl_48_20">20</a>]</p></div><div id="CDR0000062843__364"><h5>Preirradiation chemotherapy</h5><p id="CDR0000062843__365">One study demonstrated a benefit of preirradiation chemotherapy in children with near-total resection (>90% resection), with outcomes comparable to children achieving a gross-total resection followed by radiation therapy.[<a class="bk_pop" href="#CDR0000062843_rl_48_21">21</a>] The Children’s Oncology Group (COG) has completed a study of preirradiation chemotherapy in children with residual disease after up-front surgery to determine whether children treated with chemotherapy can achieve a complete response with chemotherapy or second-look surgery. Results are pending. </p><p id="CDR0000062843__366">There is no evidence that high-dose chemotherapy with stem cell rescue is of any benefit.[<a class="bk_pop" href="#CDR0000062843_rl_48_22">22</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_48_23">23</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335132/" class="def">Level of evidence: 2A</a>]</p></div></div><div id="CDR0000062843__324"><h4>Treatment options for CNS disseminated disease</h4><div id="CDR0000062843__367"><h5>Radiation therapy</h5><p id="CDR0000062843__326">Regardless of the degree of surgical
|
|
resection, these patients generally receive radiation therapy to the whole
|
|
brain and spine, along with boosts to local disease and bulk areas of
|
|
disseminated disease. The traditional local postsurgical radiation doses in
|
|
these patients have been 54 Gy to 55.8 Gy. Doses of approximately 36 Gy to
|
|
the entire neuraxis (i.e., the whole brain and spine) are also
|
|
administered but may be modulated depending on the age of the patient. Boosts
|
|
between 41.4 Gy and 50.4 Gy to bulk areas of spinal disease are
|
|
administered, with doses depending on the age of the patient and the location
|
|
of the tumor. However, there are no contemporary studies published to support this approach.</p></div><div id="CDR0000062843__368"><h5>Chemotherapy</h5><p id="CDR0000062843__369">The role of chemotherapy in the management of children with disseminated ependymoma is unproven.[<a class="bk_pop" href="#CDR0000062843_rl_48_24">24</a>]</p></div></div><div id="CDR0000062843__328"><h4>Treatment options for children younger than 3 years</h4><p id="CDR0000062843__402">Children younger than 3 years are
|
|
particularly susceptible to the adverse effects of radiation on brain
|
|
development.[<a class="bk_pop" href="#CDR0000062843_rl_48_25">25</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335152/" class="def">Level of evidence: 3iiiC</a>] Debilitating effects on growth and neurologic development have
|
|
frequently been observed, especially in younger children.[<a class="bk_pop" href="#CDR0000062843_rl_48_26">26</a>-<a class="bk_pop" href="#CDR0000062843_rl_48_28">28</a>] Consequently, radiation therapy immediately after surgery in children younger than 3 years
|
|
has historically been limited, with attempts to delay its administration through the use of chemotherapy.[<a class="bk_pop" href="#CDR0000062843_rl_48_29">29</a>-<a class="bk_pop" href="#CDR0000062843_rl_48_32">32</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_48_33">33</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335132/" class="def">Level of evidence: 2A</a>] </p><div id="CDR0000062843__370"><h5>Chemotherapy</h5><p id="CDR0000062843__390">Some, but not all, chemotherapy regimens induce objective responses in children younger than 3 years with newly diagnosed ependymoma.[<a class="bk_pop" href="#CDR0000062843_rl_48_29">29</a>-<a class="bk_pop" href="#CDR0000062843_rl_48_32">32</a>] Up to 40% of infants and young children with totally resected disease may achieve long-term survival with chemotherapy alone.[<a class="bk_pop" href="#CDR0000062843_rl_48_34">34</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335135/" class="def">Level of evidence: 2Di</a>]</p></div><div id="CDR0000062843__373"><h5>Radiation therapy</h5><p id="CDR0000062843__391">Because of the known effects of radiation on growth and neurocognitive
|
|
development, the use of radiation therapy in children younger than 3 years has been limited.</p><p id="CDR0000062843__392">Evidence (radiation therapy):</p><ol id="CDR0000062843__403"><li class="half_rhythm"><div>A retrospective review based on Surveillance, Epidemiology, and End Results data reported on 184 children younger than 3 years.[<a class="bk_pop" href="#CDR0000062843_rl_48_11">11</a>]<ul id="CDR0000062843__404"><li class="half_rhythm"><div>3-year OS was shown to be significantly better for children who received postoperative radiation therapy (81%) than for those who did not (58%, <i>P</i> = .005), even when adjusting for tumor location or degree of resection.</div></li></ul></div></li><li class="half_rhythm"><div>Conformal radiation therapy is an alternative approach for minimizing radiation-induced neurologic damage in young children with ependymoma. The need and timing of
|
|
radiation therapy for children who have successfully completed chemotherapy and
|
|
have no residual disease is still to be determined.
|
|
<ul id="CDR0000062843__405"><li class="half_rhythm"><div>The initial experience with this approach suggested that children younger than 3 years with ependymoma have neurologic deficits at diagnosis that improve with time after conformal radiation treatment.[<a class="bk_pop" href="#CDR0000062843_rl_48_14">14</a>] </div></li><li class="half_rhythm"><div>Another study suggested that there was a trend for intellectual deterioration over time even in older children treated with localized radiation therapy.[<a class="bk_pop" href="#CDR0000062843_rl_48_25">25</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335152/" class="def">Level of evidence: 3iiiC</a>] </div></li></ul></div></li></ol><p id="CDR0000062843__394">Conformal radiation approaches, such as <a href="/books/n/pdqcis/glossary/def-item/glossary_CDR0000270731/" class="def">3-dimensional conformal radiation therapy</a>, that minimize damage to normal brain tissue and <a href="/books/n/pdqcis/glossary/def-item/glossary_CDR0000534234/" class="def">charged-particle radiation therapy</a>, such as proton-beam therapy, are under evaluation for infants and children with ependymoma.[<a class="bk_pop" href="#CDR0000062843_rl_48_14">14</a>,<a class="bk_pop" href="#CDR0000062843_rl_48_35">35</a>] When analyzing neurologic outcome after treatment of young children with ependymoma, it is important to consider that not all long-term deficits can be ascribed to radiation therapy because deficits may be present in young children before therapy begins.[<a class="bk_pop" href="#CDR0000062843_rl_48_14">14</a>] For example, the presence of hydrocephalus at diagnosis is associated with lower intelligence quotient as measured after surgical resection and before administration of radiation therapy.[<a class="bk_pop" href="#CDR0000062843_rl_48_36">36</a>]</p><p id="CDR0000062843__395">The recently completed COG protocol (<a href="http://cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=69086" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ACNS0121</a> [<a href="https://clinicaltrials.gov/show/NCT00027846" title="Study NCT00027846" ref="pagearea=body&targetsite=external&targetcat=link&targettype=clinical-trial">NCT00027846</a>]) for children with ependymoma includes children aged 1 year and older. The trial is a prospective evaluation of postoperative radiation therapy. Results are forthcoming.</p></div></div></div><div id="CDR0000062843__132"><h3>Treatment Options Under Clinical Evaluation for Newly Diagnosed Childhood Ependymoma or Anaplastic Ependymoma</h3><p id="CDR0000062843__277">The following is an example of a national and/or institutional clinical trial that is currently being conducted or is under analysis. Information about ongoing clinical trials is available from the <a href="http://www.cancer.gov/about-cancer/treatment/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI website</a>.</p><ol id="CDR0000062843__350"><li class="half_rhythm"><div><b><a href="http://cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=668560" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COG-ACNS0831 (NCT01096368)</a></b> (Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma)<b>:</b> The purpose of this phase III trial is as follows:<h4><span class="title">No Residual Disease; No Disseminated Disease</span></h4><ul id="CDR0000062843__279"><li class="half_rhythm"><div>The trial will determine whether adding chemotherapy after radiation therapy results in improved survival over radiation therapy alone.</div></li><li class="half_rhythm"><div>The trial will determine whether children with supratentorial nonanaplastic ependymoma who receive a complete resection or who achieve a complete remission after being treated with chemotherapy can be successfully treated without radiation therapy.</div></li></ul><h4><span class="title">Residual Disease; No Disseminated Disease</span></h4><ul id="CDR0000062843__280"><li class="half_rhythm"><div>The trial will determine whether adding chemotherapy before and after radiation therapy results in improved survival compared with previous studies of children who did not receive additional chemotherapy after radiation treatment.</div></li></ul></div></li></ol><div id="CDR0000062843__TrialSearch_132_sid_8"><h4>Current Clinical Trials</h4><p id="CDR0000062843__TrialSearch_132_20">Check the list of NCI-supported cancer clinical trials that are now accepting patients with
|
|
<a href="http://www.cancer.gov/search/ClinicalTrialsLink.aspx?Diagnosis=43455&tt=1&format=2&cn=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">newly diagnosed childhood ependymoma</a>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</p><p id="CDR0000062843__TrialSearch_132_21">General information about clinical trials is also available from the <a href="http://www.cancer.gov/about-cancer/treatment/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI website</a>.</p></div></div><div id="CDR0000062843_rl_48"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062843_rl_48_1">van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, et al.: Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 97 (4): 827-35, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12405370" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12405370</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_2">Abdel-Wahab M, Etuk B, Palermo J, et al.: Spinal cord gliomas: A multi-institutional retrospective analysis. Int J Radiat Oncol Biol Phys 64 (4): 1060-71, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16373081" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16373081</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_3">Kothbauer KF: Neurosurgical management of intramedullary spinal cord tumors in children. Pediatr Neurosurg 43 (3): 222-35, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17409792" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17409792</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_4">Zacharoulis S, Ji L, Pollack IF, et al.: Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors. Pediatr Blood Cancer 50 (2): 231-5, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/17610266" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17610266</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_5">Merchant TE, Li C, Xiong X, et al.: Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10 (3): 258-66, 2009. [<a href="/pmc/articles/PMC3615425/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3615425</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19274783" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19274783</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_6">Cage TA, Clark AJ, Aranda D, et al.: A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas. J Neurosurg Pediatr 11 (6): 673-81, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23540528" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23540528</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_7">Volpp PB, Han K, Kagan AR, et al.: Outcomes in treatment for intradural spinal cord ependymomas. Int J Radiat Oncol Biol Phys 69 (4): 1199-204, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17689025" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17689025</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_8">Hukin J, Epstein F, Lefton D, et al.: Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 29 (1): 40-5, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9755311" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9755311</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_9">Little AS, Sheean T, Manoharan R, et al.: The management of completely resected childhood intracranial ependymoma: the argument for observation only. Childs Nerv Syst 25 (3): 281-4, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19153750" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19153750</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_10">Venkatramani R, Dhall G, Patel M, et al.: Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer 58 (3): 380-3, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/21370439" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21370439</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_11">Koshy M, Rich S, Merchant TE, et al.: Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J Neurooncol 105 (3): 583-90, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21637963" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21637963</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_12">Combs SE, Kelter V, Welzel T, et al.: Influence of radiotherapy treatment concept on the outcome of patients with localized ependymomas. Int J Radiat Oncol Biol Phys 71 (4): 972-8, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18337022" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18337022</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_13">Schroeder TM, Chintagumpala M, Okcu MF, et al.: Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys 71 (4): 987-93, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18258381" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18258381</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_14">Merchant TE, Mulhern RK, Krasin MJ, et al.: Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22 (15): 3156-62, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15284268" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15284268</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_15">Landau E, Boop FA, Conklin HM, et al.: Supratentorial ependymoma: disease control, complications, and functional outcomes after irradiation. Int J Radiat Oncol Biol Phys 85 (4): e193-9, 2013. [<a href="/pmc/articles/PMC3705553/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3705553</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23245280" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23245280</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_16">Pejavar S, Polley MY, Rosenberg-Wohl S, et al.: Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol 106 (2): 367-75, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/21826561" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21826561</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_17">Macdonald SM, Sethi R, Lavally B, et al.: Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro Oncol 15 (11): 1552-9, 2013. [<a href="/pmc/articles/PMC3813421/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3813421</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24101739" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24101739</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_18">Zacharoulis S, Levy A, Chi SN, et al.: Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49 (1): 34-40, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/16874765" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16874765</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_19">Massimino M, Solero CL, Garrè ML, et al.: Second-look surgery for ependymoma: the Italian experience. J Neurosurg Pediatr 8 (3): 246-50, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21882914" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21882914</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_20">Wahab SH, Simpson JR, Michalski JM, et al.: Long term outcome with post-operative radiation therapy for spinal canal ependymoma. J Neurooncol 83 (1): 85-9, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17206474" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17206474</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_21">Garvin JH Jr, Selch MT, Holmes E, et al.: Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: a report from the Children's Oncology Group. Pediatr Blood Cancer 59 (7): 1183-9, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22949057" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22949057</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_22">Grill J, Kalifa C, Doz F, et al.: A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study. Pediatr Neurosurg 25 (1): 7-12, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/9055328" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9055328</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_23">Venkatramani R, Ji L, Lasky J, et al.: Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trial. J Neurooncol 113 (2): 285-91, 2013. [<a href="/pmc/articles/PMC4119804/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4119804</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23508296" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23508296</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_24">Bouffet E, Capra M, Bartels U: Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst 25 (10): 1293-301, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19360417" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19360417</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_25">von Hoff K, Kieffer V, Habrand JL, et al.: Impairment of intellectual functions after surgery and posterior fossa irradiation in children with ependymoma is related to age and neurologic complications. BMC Cancer 8: 15, 2008. [<a href="/pmc/articles/PMC2254428/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2254428</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18208613" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18208613</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_26">Packer RJ, Sutton LN, Atkins TE, et al.: A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 70 (5): 707-13, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2709111" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2709111</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_27">Johnson DL, McCabe MA, Nicholson HS, et al.: Quality of long-term survival in young children with medulloblastoma. J Neurosurg 80 (6): 1004-10, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/8189255" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8189255</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_28">Packer RJ, Sutton LN, Goldwein JW, et al.: Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 74 (3): 433-40, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/1847194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1847194</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_29">Duffner PK, Horowitz ME, Krischer JP, et al.: The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-oncol 1 (2): 152-61, 1999. [<a href="/pmc/articles/PMC1920752/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1920752</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11554387" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11554387</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_30">Duffner PK, Horowitz ME, Krischer JP, et al.: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328 (24): 1725-31, 1993. [<a href="https://pubmed.ncbi.nlm.nih.gov/8388548" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8388548</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_31">Geyer JR, Sposto R, Jennings M, et al.: Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23 (30): 7621-31, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16234523" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16234523</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_32">Grill J, Le Deley MC, Gambarelli D, et al.: Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19 (5): 1288-96, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11230470" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11230470</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_33">Massimino M, Gandola L, Barra S, et al.: Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy. Int J Radiat Oncol Biol Phys 80 (3): 807-14, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/20646868" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20646868</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_34">Grundy RG, Wilne SA, Weston CL, et al.: Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8 (8): 696-705, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17644039" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17644039</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_35">MacDonald SM, Safai S, Trofimov A, et al.: Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 71 (4): 979-86, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18325681" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18325681</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_48_36">Merchant TE, Lee H, Zhu J, et al.: The effects of hydrocephalus on intelligence quotient in children with localized infratentorial ependymoma before and after focal radiation therapy. J Neurosurg 101 (2 Suppl): 159-68, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15835103" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15835103</span></a>]</div></li></ol></div></div><div id="CDR0000062843__61"><h2 id="_CDR0000062843__61_">Treatment of Recurrent Childhood Ependymoma</h2><p id="CDR0000062843__62">Recurrence is not uncommon for all grades of ependymoma
|
|
and may develop many years after initial treatment.[<a class="bk_pop" href="#CDR0000062843_rl_61_1">1</a>] Late recurrence
|
|
beyond 10 to 15 years has been reported.[<a class="bk_pop" href="#CDR0000062843_rl_61_2">2</a>,<a class="bk_pop" href="#CDR0000062843_rl_61_3">3</a>] Disease generally recurs at the
|
|
primary tumor site,[<a class="bk_pop" href="#CDR0000062843_rl_61_4">4</a>,<a class="bk_pop" href="#CDR0000062843_rl_61_5">5</a>] although concomitant neuraxis dissemination may also be seen. Systemic
|
|
relapse is extremely rare. At time of relapse, a complete evaluation for
|
|
extent of recurrence is indicated for all patients. </p><div id="CDR0000062843__375"><h3>Surgery</h3><p id="CDR0000062843__376">The need for further surgical
|
|
intervention is individualized based on the following:</p><ul id="CDR0000062843__396"><li class="half_rhythm"><div>Extent of the tumor.</div></li><li class="half_rhythm"><div>Length of time between initial treatment and the reappearance of the recurrent
|
|
lesion.</div></li><li class="half_rhythm"><div>Clinical picture.</div></li></ul><p id="CDR0000062843__397">In some cases, surgically accessible lesions may be treated alternatively by radiation therapy.</p></div><div id="CDR0000062843__377"><h3>Radiation Therapy and/or Chemotherapy</h3><p id="CDR0000062843__378">Patients with recurrent ependymomas who have
|
|
not previously received radiation therapy and/or chemotherapy should be
|
|
considered for treatment with the following modalities:[<a class="bk_pop" href="#CDR0000062843_rl_61_6">6</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335151/" class="def">Level of evidence: 3iiiB</a>] </p><ol id="CDR0000062843__352"><li class="half_rhythm"><div>Focal retreatment with various radiation modalities, including <a href="/books/n/pdqcis/glossary/def-item/glossary_CDR0000046701/" class="def">stereotactic radiosurgery</a>.[<a class="bk_pop" href="#CDR0000062843_rl_61_7">7</a>,<a class="bk_pop" href="#CDR0000062843_rl_61_8">8</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335150/" class="def">Level of evidence: 3iiiA</a>]; [<a class="bk_pop" href="#CDR0000062843_rl_61_9">9</a>,<a class="bk_pop" href="#CDR0000062843_rl_61_10">10</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000335153/" class="def">Level of evidence: 3iiiDi</a>]</div></li><li class="half_rhythm"><div>Active anticancer agents, including
|
|
cyclophosphamide, cisplatin, carboplatin, lomustine, and etoposide.</div></li></ol><p id="CDR0000062843__341"> Regardless of treatment strategy, the prognosis for patients with recurrence is poor.[<a class="bk_pop" href="#CDR0000062843_rl_61_1">1</a>] Entry into
|
|
studies of novel therapeutic approaches should be considered.</p></div><div id="CDR0000062843__247"><h3>Treatment Options Under Clinical Evaluation for Recurrent Childhood Ependymoma</h3><p id="CDR0000062843__248">Early-phase therapeutic trials may be available for selected patients. These trials may be available via Children's Oncology Group, the Pediatric Brain Tumor Consortium, or other entities. Information about ongoing clinical trials is available from the <a href="http://www.cancer.gov/about-cancer/treatment/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI website</a>.</p><div id="CDR0000062843__TrialSearch_247_sid_8"><h4>Current Clinical Trials</h4><p id="CDR0000062843__TrialSearch_247_20">Check the list of NCI-supported cancer clinical trials that are now accepting patients with
|
|
<a href="http://www.cancer.gov/search/ClinicalTrialsLink.aspx?Diagnosis=43456&tt=1&format=2&cn=1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">recurrent childhood ependymoma</a>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</p><p id="CDR0000062843__TrialSearch_247_21">General information about clinical trials is also available from the <a href="http://www.cancer.gov/about-cancer/treatment/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI website</a>.</p></div></div><div id="CDR0000062843_rl_61"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062843_rl_61_1">Zacharoulis S, Ashley S, Moreno L, et al.: Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst 26 (7): 905-11, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20039045" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20039045</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_2">Pollack IF, Gerszten PC, Martinez AJ, et al.: Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 37 (4): 655-66; discussion 666-7, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8559293" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8559293</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_3">Vanuytsel LJ, Bessell EM, Ashley SE, et al.: Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 23 (2): 313-9, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1587752" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1587752</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_4">Goldwein JW, Corn BW, Finlay JL, et al.: Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas? Cancer 67 (11): 2766-71, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/2025840" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2025840</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_5">Merchant TE, Haida T, Wang MH, et al.: Anaplastic ependymoma: treatment of pediatric patients with or without craniospinal radiation therapy. J Neurosurg 86 (6): 943-9, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9171172" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9171172</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_6">Messahel B, Ashley S, Saran F, et al.: Relapsed intracranial ependymoma in children in the UK: patterns of relapse, survival and therapeutic outcome. Eur J Cancer 45 (10): 1815-23, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19427780" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19427780</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_7">Kano H, Yang HC, Kondziolka D, et al.: Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. J Neurosurg Pediatr 6 (5): 417-23, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/21039163" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21039163</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_8">Bouffet E, Hawkins CE, Ballourah W, et al.: Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys 83 (5): 1541-8, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22245198" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22245198</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_9">Merchant TE, Boop FA, Kun LE, et al.: A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 71 (1): 87-97, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18406885" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18406885</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062843_rl_61_10">Kano H, Niranjan A, Kondziolka D, et al.: Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery 64 (2): 279-87; discussion 287-8, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19190457" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19190457</span></a>]</div></li></ol></div></div><div id="CDR0000062843__79"><h2 id="_CDR0000062843__79_">Changes to This Summary (08/14/2015)</h2><p id="CDR0000062843__86">The PDQ cancer information summaries are reviewed regularly and updated as
|
|
new information becomes available. This section describes the latest
|
|
changes made to this summary as of the date above.</p><p id="CDR0000062843__419">Editorial changes were made to this summary.</p><p id="CDR0000062843__disclaimerHP_3">This summary is written and maintained by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Pediatric Treatment Editorial Board</a>, which is
|
|
editorially independent of NCI. The summary reflects an independent review of
|
|
the literature and does not represent a policy statement of NCI or NIH. More
|
|
information about summary policies and the role of the PDQ Editorial Boards in
|
|
maintaining the PDQ summaries can be found on the <a href="#CDR0000062843__AboutThis_1">About This PDQ Summary</a> and <a href="http://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
|
|
</p></div><div id="CDR0000062843__AboutThis_1"><h2 id="_CDR0000062843__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000062843__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000062843__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood ependymoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000062843__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000062843__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Pediatric Treatment Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000062843__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000062843__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000062843__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p>The lead reviewers for Childhood Ependymoma Treatment are:</p><ul><li class="half_rhythm"><div>Kenneth J. Cohen, MD, MBA (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital)</div></li><li class="half_rhythm"><div>Louis S. Constine, MD (James P. Wilmot Cancer Center at University of Rochester Medical Center)</div></li><li class="half_rhythm"><div>Roger J. Packer, MD (Children's National Medical Center)</div></li><li class="half_rhythm"><div>Malcolm A. Smith, MD, PhD (National Cancer Institute)</div></li></ul><p id="CDR0000062843__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="http://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000062843__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000062843__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <a href="/books/n/pdqcis/CDR0000062796/">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000062843__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000062843__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000062843__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000062843__AboutThis_15">National Cancer Institute: PDQ® Childhood Ependymoma Treatment. Bethesda, MD: National Cancer Institute. Date last modified <MM/DD/YYYY>. Available at: <a href="http://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq</a>. Accessed <MM/DD/YYYY>.</p><p id="CDR0000062843__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="http://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
|
</p></div><div id="CDR0000062843__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000062843__AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="http://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000062843__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000062843__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="http://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="http://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div><div id="CDR0000062843__GetMore_3"><h2 id="_CDR0000062843__GetMore_3_">Get More Information From NCI</h2><p id="CDR0000062843__GetMore_15"><i><b>Call 1-800-4-CANCER</b></i></p><p id="CDR0000062843__GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.</p><p id="CDR0000062843__GetMore_25"><i><b>Chat online
|
|
</b></i></p><p id="CDR0000062843__GetMore_26">The <a href="https://livehelp.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI's LiveHelp®</a> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI websites and answer questions about cancer.
|
|
</p><p id="CDR0000062843__GetMore_27"><i><b>Write to us</b></i></p><p id="CDR0000062843__GetMore_28">For more information from the NCI, please write to this address:</p><ul id="CDR0000062843__GetMore_29" class="simple-list"><li class="half_rhythm"><div>NCI Public Inquiries Office</div></li><li class="half_rhythm"><div>9609 Medical Center Dr. </div></li><li class="half_rhythm"><div>Room 2E532 MSC 9760</div></li><li class="half_rhythm"><div>Bethesda, MD 20892-9760</div></li></ul><p id="CDR0000062843__GetMore_17"><i><b>Search the NCI websites</b></i></p><p id="CDR0000062843__GetMore_18">The <a href="http://www.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI website</a> provides online access to information on cancer, clinical trials, and other websites and organizations that offer support and resources for cancer patients and their families. For a quick search, use the search box in the upper right corner of each web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen web pages that are most closely related to the search term entered.</p><p id="CDR0000062843__GetMore_30">There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</p><p id="CDR0000062843__GetMore_19"><i><b>Find Publications</b></i></p><p id="CDR0000062843__GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the <a href="https://pubs.cancer.gov/ncipl" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI Publications Locator</a>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</p></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK65935</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26389373" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">26389373</a></span></div></div></div>
|
|
|
|
</div>
|
|
|
|
<!-- Custom content below content -->
|
|
<div class="col4">
|
|
|
|
</div>
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<!-- Custom contetnt below bottom nav -->
|
|
<div class="col5">
|
|
|
|
</div>
|
|
</div>
|
|
|
|
<div id="rightcolumn" class="four_col col last">
|
|
<!-- Custom content above discovery portlets -->
|
|
<div class="col6">
|
|
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK65935&db=books">Share</a></div>
|
|
|
|
</div>
|
|
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65935.1/?report=reader">PubReader</a></li><li><a href="/books/NBK65935.1/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK65935" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK65935" style="display:none" title="Cite this Page"><div class="bk_tt">PDQ Pediatric Treatment Editorial Board. Childhood Ependymoma Treatment (PDQ®): Health Professional Version. 2015 Aug 14. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></div></div></li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Version History</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter shutter_closed" title="Show/hide content" remembercollapsed="true" pgsec_name="version_history" id="Shutter"></a></div><div class="portlet_content" style="display: none;"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><span class="bk_col_itm"><a href="/books/NBK65935.24/">NBK65935.24</a></span> January 6, 2025</li><li><span class="bk_col_itm"><a href="/books/NBK65935.23/">NBK65935.23</a></span> October 15, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65935.22/">NBK65935.22</a></span> April 16, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65935.21/">NBK65935.21</a></span> February 9, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65935.20/">NBK65935.20</a></span> January 4, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65935.19/">NBK65935.19</a></span> June 7, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK65935.18/">NBK65935.18</a></span> August 5, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65935.17/">NBK65935.17</a></span> February 2, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65935.16/">NBK65935.16</a></span> February 9, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK65935.15/">NBK65935.15</a></span> September 25, 2020</li><li><span class="bk_col_itm"><a href="/books/NBK65935.14/">NBK65935.14</a></span> March 20, 2020</li><li><span class="bk_col_itm"><a href="/books/NBK65935.13/">NBK65935.13</a></span> October 23, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65935.12/">NBK65935.12</a></span> September 9, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65935.11/">NBK65935.11</a></span> August 13, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65935.10/">NBK65935.10</a></span> June 13, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65935.9/">NBK65935.9</a></span> January 29, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65935.8/">NBK65935.8</a></span> April 2, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65935.7/">NBK65935.7</a></span> January 24, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65935.6/">NBK65935.6</a></span> September 18, 2017</li><li><span class="bk_col_itm"><a href="/books/NBK65935.5/">NBK65935.5</a></span> April 6, 2017</li><li><span class="bk_col_itm"><a href="/books/NBK65935.4/">NBK65935.4</a></span> August 12, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65935.3/">NBK65935.3</a></span> May 23, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65935.2/">NBK65935.2</a></span> September 24, 2015</li><li><span class="bk_col_itm">NBK65935.1</span> August 14, 2015 (Displayed Version)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#CDR0000062843__1" ref="log$=inpage&link_id=inpage">General Information About Childhood Ependymoma</a></li><li><a href="#CDR0000062843__35" ref="log$=inpage&link_id=inpage"> Histopathologic Classification of Childhood Ependymal Tumors</a></li><li><a href="#CDR0000062843__40" ref="log$=inpage&link_id=inpage">Stage Information for Childhood Ependymoma</a></li><li><a href="#CDR0000062843__42" ref="log$=inpage&link_id=inpage">Treatment Option Overview for Childhood Ependymoma</a></li><li><a href="#CDR0000062843__298" ref="log$=inpage&link_id=inpage">Treatment of Newly Diagnosed Childhood Subependymoma</a></li><li><a href="#CDR0000062843__302" ref="log$=inpage&link_id=inpage">Treatment of Newly Diagnosed Childhood Myxopapillary Ependymoma</a></li><li><a href="#CDR0000062843__48" ref="log$=inpage&link_id=inpage"> Treatment of Newly Diagnosed Childhood Ependymoma or Anaplastic Ependymoma</a></li><li><a href="#CDR0000062843__61" ref="log$=inpage&link_id=inpage">Treatment of Recurrent Childhood Ependymoma</a></li><li><a href="#CDR0000062843__79" ref="log$=inpage&link_id=inpage">Changes to This Summary (08/14/2015)</a></li><li><a href="#CDR0000062843__AboutThis_1" ref="log$=inpage&link_id=inpage">About This PDQ Summary</a></li><li><a href="#CDR0000062843__GetMore_3" ref="log$=inpage&link_id=inpage">Get More Information From NCI</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related publications</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65742/">Patient Version</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389330" ref="ordinalpos=1&linkpos=1&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Craniopharyngioma Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Craniopharyngioma Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Pediatric Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389243" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Rhabdomyosarcoma Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Rhabdomyosarcoma Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Pediatric Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31909946" ref="ordinalpos=1&linkpos=3&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Melanoma Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Melanoma Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Pediatric Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31909945" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Chordoma Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Chordoma Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Pediatric Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29337483" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Esthesioneuroblastoma Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Childhood Esthesioneuroblastoma Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Pediatric Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=26389373" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=26389373" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c9a1a3b15b832ebc4cea64">Childhood Ependymoma Treatment (PDQ®) - PDQ Cancer Information Summaries</a><div class="ralinkpop offscreen_noflow">Childhood Ependymoma Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
|
|
|
<!-- Custom content below discovery portlets -->
|
|
<div class="col7">
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
<!-- Custom content after all -->
|
|
<div class="col8">
|
|
|
|
</div>
|
|
<div class="col9">
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
|
<script type="text/javascript">
|
|
(function($){
|
|
$('.skiplink').each(function(i, item){
|
|
var href = $($(item).attr('href'));
|
|
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
|
$(item).on('click', function(event){
|
|
event.preventDefault();
|
|
$.scrollTo(href, 0, {
|
|
onAfter: function(){
|
|
href.focus();
|
|
}
|
|
});
|
|
});
|
|
});
|
|
})(jQuery);
|
|
</script>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<div class="footer" id="footer">
|
|
<section class="icon-section">
|
|
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
|
<div class="grid-container container">
|
|
<div class="icon-section_container">
|
|
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11 {
|
|
fill: #737373;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>Twitter</title>
|
|
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>Facebook</title>
|
|
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>LinkedIn</title>
|
|
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11,
|
|
.cls-12 {
|
|
fill: #737373;
|
|
}
|
|
|
|
.cls-11 {
|
|
fill-rule: evenodd;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>GitHub</title>
|
|
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
|
</path>
|
|
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
|
</path>
|
|
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
|
</path>
|
|
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
|
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
|
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
|
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
|
<title>NCBI Insights Blog</title>
|
|
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
|
</svg>
|
|
</a>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
|
|
<section class="container-fluid bg-primary">
|
|
<div class="container pt-5">
|
|
<div class="row mt-3">
|
|
<div class="col-lg-3 col-12">
|
|
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
|
<ul class="list-inline social_media">
|
|
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st20 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st30 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Twitter</title>
|
|
<g>
|
|
<g>
|
|
<g>
|
|
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
|
</g>
|
|
</svg></a></li>
|
|
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
|
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st10 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st110 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Facebook</title>
|
|
<g>
|
|
<g>
|
|
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
|
</svg>
|
|
</a></li>
|
|
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<title>Youtube</title>
|
|
<style type="text/css">
|
|
.st4 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
|
|
.st5 {
|
|
fill: #FFFFFF;
|
|
}
|
|
</style>
|
|
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
|
<g transform="translate(0,-952.36218)">
|
|
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
|
</g>
|
|
</svg></a></li>
|
|
</ul>
|
|
</div>
|
|
<div class="col-lg-3 col-12">
|
|
<p class="address_footer text-white">National Library of Medicine<br />
|
|
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
|
Bethesda, MD 20894</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
|
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
|
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
|
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
|
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-12 centered-lg">
|
|
<nav class="bottom-links">
|
|
<ul class="mt-3">
|
|
<li>
|
|
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
|
</li>
|
|
</ul>
|
|
</nav>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK65935&ncbi_domain=pdqcis&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK65935.1/&ncbi_pagename=Childhood Ependymoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |